journal article·2023-03Open access

Cancer Cells Enter an Adaptive Persistence to Survive Radiotherapy and Repopulate Tumor

Yucui Zhao, Tingting Lu, Yanwei Song, Yanqin Wen, Zheng Deng, Jiahui Fan, Minghui Zhao, Ruyi Zhao, Yuntao Luo, Jianzhu xie, Binjie Hu, Haoran Sun, Yiwei Wang, Sijia He, Yanping Gong, Jin Cheng, Xinjian Liu, Liang Yu, Jikun Li, Chuanyuan Li, Yongyong Shi, Qian Huang

Advanced Science· Volume 10· Issue 8

Abstract

Abstract Repopulation of residual tumor cells impedes curative radiotherapy, yet the mechanism is not fully understood. It is recently appreciated that cancer cells adopt a transient persistence to survive the stress of chemo‐ or targeted therapy and facilitate eventual relapse. Here, it is shown that cancer cells likewise enter a “radiation‐tolerant persister” (RTP) state to evade radiation pressure in vitro and in vivo. RTP cells are characterized by enlarged cell size with complex karyotype, activated type I interferon pathway and two gene patterns represented by CST3 and SNCG. RTP cells have the potential to regenerate progenies via viral budding‐like division, and type I interferon‐mediated antiviral signaling impaired progeny production. Depleting CST3 or SNCG does not attenuate the formation of RTP cells, but can suppress RTP cells budding with impaired tumor repopulation. Interestingly, progeny cells produced by RTP cells actively lose their aberrant chromosomal fragments and gradually recover back to a chromosomal constitution similar to their unirradiated parental cells. Collectively, this study reveals a novel mechanism of tumor repopulation, i.e., cancer cell populations employ a reversible radiation‐persistence by poly‐ and de‐polyploidization to survive radiotherapy and repopulate the tumor, providing a new therapeutic concept to improve outcome of patients receiving radiotherapy.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: CRISPR and Genetic Engineering · PARP inhibition in cancer therapy · Single-cell and spatial transcriptomics

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Shanghai Key Laboratory for Pancreatic Diseases and Cancer Center Shanghai General Hospital Shanghai Jiao Tong University School of Medicine Shanghai 201620 China

Bio‐X Institutes Key Laboratory for the Genetics of Developmental and Neuropsychiatric Disorders (Ministry of Education) Shanghai Jiao Tong University Shanghai 200030 China

Zhejiang Provincial Key Laboratory of Pancreatic Disease The First Affiliated Hospital Zhejiang University School of Medicine Hangzhou 310009 China

Department of Biochemistry School of Medicine Sun Yat‐sen University Shenzhen 518107 China

Department of General Surgery Shanghai General Hospital Shanghai Jiao Tong University School of Medicine Shanghai 201620 China

Department of Dermatology Duke University Medical Center Box 3135 Durham NC 27710 USA

Biomedical Sciences Institute of Qingdao University (Qingdao Branch of SJTU Bio‐X Institutes) Qingdao University Qingdao 266003 China

Funding

National Natural Science Foundation of China

References (80)

Show source-provided references
1. 10.1016/S0140-6736(21)00233-610.1016/S0140-6736(21)00233-6 ↗
2. 10.1038/nrc395810.1038/nrc3958 ↗
3. 10.1038/nrc165010.1038/nrc1650 ↗
4. 10.1016/j.trecan.2020.01.01810.1016/j.trecan.2020.01.018 ↗
5. 10.1038/nm.238510.1038/nm.2385 ↗
6. 10.1016/j.cell.2010.02.02710.1016/j.cell.2010.02.027 ↗
7. 10.1126/science.aav447410.1126/science.aav4474 ↗
8. 10.1038/nrmicro.2017.4210.1038/nrmicro.2017.42 ↗
9. 10.1016/j.cell.2020.10.02710.1016/j.cell.2020.10.027 ↗
10. 10.1038/bjc.2017.7810.1038/bjc.2017.78 ↗
11. 10.1038/onc.2013.9610.1038/onc.2013.96 ↗
12. 10.1002/pros.2387710.1002/pros.23877 ↗
13. 10.1016/j.cellbi.2008.06.00310.1016/j.cellbi.2008.06.003 ↗
14. 10.1016/j.tcb.2018.02.00610.1016/j.tcb.2018.02.006 ↗
15. 10.1186/s13046-015-0277-810.1186/s13046-015-0277-8 ↗
16. 10.1158/1078-0432.CCR-15-018310.1158/1078-0432.CCR-15-0183 ↗
17. 10.1038/ng.12710.1038/ng.127 ↗
18. 10.1038/onc.2008.21310.1038/onc.2008.213 ↗
19. 10.1126/science.107253010.1126/science.1072530 ↗
20. 10.1186/gb-2012-13-8-r7110.1186/gb-2012-13-8-r71 ↗
21. 10.1016/j.ccell.2020.04.01710.1016/j.ccell.2020.04.017 ↗
22. 10.1016/j.celrep.2018.03.10210.1016/j.celrep.2018.03.102 ↗
23. 10.1038/s41577-020-0288-310.1038/s41577-020-0288-3 ↗
24. 10.1038/s41591-018-0017-710.1038/s41591-018-0017-7 ↗
25. 10.1038/nature0846010.1038/nature08460 ↗
26. 10.1146/annurev-immunol-032713-12023110.1146/annurev-immunol-032713-120231 ↗
27. 10.1146/annurev-virology-092818-01575610.1146/annurev-virology-092818-015756 ↗
28. 10.1053/j.seminoncol.2014.02.00210.1053/j.seminoncol.2014.02.002 ↗
29. 10.1016/j.ccell.2020.12.00210.1016/j.ccell.2020.12.002 ↗
30. 10.1016/j.cell.2020.11.01810.1016/j.cell.2020.11.018 ↗
31. 10.1158/2159-8290.CD-20-137510.1158/2159-8290.CD-20-1375 ↗
32. 10.1016/j.devcel.2015.10.01110.1016/j.devcel.2015.10.011 ↗
33. 10.1016/j.ccr.2013.06.00510.1016/j.ccr.2013.06.005 ↗
34. 10.1073/pnas.181821011610.1073/pnas.1818210116 ↗
35. 10.1016/j.stem.2022.07.00810.1016/j.stem.2022.07.008 ↗
36. 10.1038/s41586-019-1154-y10.1038/s41586-019-1154-y ↗
37. 10.1073/pnas.111885710910.1073/pnas.1118857109 ↗
38. 10.1038/s41586-022-05402-910.1038/s41586-022-05402-9 ↗
39. 10.1038/nmeth.440210.1038/nmeth.4402 ↗
40. 10.1002/path.505110.1002/path.5051 ↗
41. 10.1016/j.ccell.2022.01.00410.1016/j.ccell.2022.01.004 ↗
42. 10.1073/pnas.080924210510.1073/pnas.0809242105 ↗
43. 10.1186/1471-2164-14-33610.1186/1471-2164-14-336 ↗
44. 10.1016/S1470-2045(18)30080-910.1016/S1470-2045(18)30080-9 ↗
45. 10.1172/jci.insight.14871710.1172/jci.insight.148717 ↗
46. 10.1016/j.bcp.2018.11.00410.1016/j.bcp.2018.11.004 ↗
47. 10.1038/s41573-019-0044-110.1038/s41573-019-0044-1 ↗
48. 10.1002/1878-0261.1217410.1002/1878-0261.12174 ↗
49. 10.1016/j.stem.2016.11.00310.1016/j.stem.2016.11.003 ↗
50. 10.1038/s41467-022-30641-910.1038/s41467-022-30641-9 ↗
51. 10.1016/j.ccell.2017.07.00210.1016/j.ccell.2017.07.002 ↗
52. 10.1016/j.molmed.2019.02.00610.1016/j.molmed.2019.02.006 ↗
53. 10.1016/j.semcancer.2020.11.01610.1016/j.semcancer.2020.11.016 ↗
54. 10.1016/j.semcancer.2020.12.00910.1016/j.semcancer.2020.12.009 ↗
55. 10.1038/s41568-018-0084-610.1038/s41568-018-0084-6 ↗
56. 10.3389/fcell.2021.67634410.3389/fcell.2021.676344 ↗
57. 10.4161/cbt.3.2.66310.4161/cbt.3.2.663 ↗
58. 10.1093/jnci/djaa19010.1093/jnci/djaa190 ↗
59. 10.1016/j.it.2019.10.00910.1016/j.it.2019.10.009 ↗
60. 10.18632/oncotarget.842010.18632/oncotarget.8420 ↗
61. 10.1038/nm.286110.1038/nm.2861 ↗
62. 10.1158/2159-8290.CD-19-076110.1158/2159-8290.CD-19-0761 ↗
63. 10.1016/j.celrep.2020.10788710.1016/j.celrep.2020.107887 ↗
64. 10.1093/cvr/cvq13810.1093/cvr/cvq138 ↗
65. 10.1093/eurheartj/ehab11010.1093/eurheartj/ehab110 ↗
66. 10.1016/j.arr.2016.06.00310.1016/j.arr.2016.06.003 ↗
67. 10.1038/icb.2014.12110.1038/icb.2014.121 ↗
68. 10.1016/j.biocel.2009.05.00510.1016/j.biocel.2009.05.005 ↗
69. 10.1096/fj.07-8379rev10.1096/fj.07-8379rev ↗
70. 10.18632/oncotarget.2541510.18632/oncotarget.25415 ↗
71. 10.1038/onc.2014.12610.1038/onc.2014.126 ↗
72. 10.1016/j.yexcr.2010.10.01310.1016/j.yexcr.2010.10.013 ↗
73. 10.1016/j.trecan.2020.04.00110.1016/j.trecan.2020.04.001 ↗
74. 10.3233/JAD-17089410.3233/JAD-170894 ↗
75. 10.1126/science.282.5393.149710.1126/science.282.5393.1497 ↗
76. 10.1002/cncr.2602110.1002/cncr.26021 ↗
77. 10.1016/j.jim.2009.06.00810.1016/j.jim.2009.06.008 ↗
78. 10.1186/s13046-015-0166-110.1186/s13046-015-0166-1 ↗
79. 10.1038/nprot.2013.14310.1038/nprot.2013.143 ↗
80. 10.1038/s41467-018-07901-810.1038/s41467-018-07901-8 ↗